EGFR and ovarian carcinoma: It is strongly suggested that overexpressed RUNX1 regulate the abnormal proliferation of ovarian cancer cells through the EGFR-AKT-STAT3 axis and RUNX1 work as a potential target for ovarian cancer treatment.